In ptns with IgA nephropathy (IgANp), im/m therapy is generally preserved for ptns who’re at higher risk for disease progress.
In ptns with IgA nephropathy (IgANp), im/m therapy is generally preserved for ptns who’re at higher risk for disease progress; however, tools recognizing which ptns are likely to benefit from therapy are currently deficient.
Study: almost more than 600 Chinese ptns with IgANp at higher risk for disease progress and had received im/m therapy for an average of 18 mo., increased levels of macrophage infiltration within glomeruli on renal biopsy were mostly associated with a markedly higher probability of a better response to im/m therapy in comparison with lowered levels.
The recently given data (i.e., the magnitude of macrophage infiltrative intensity) if combined with associated clinical and histological data may be precisely help in prediction of the response to im/m. therapy. However, meanwhile these data may help identifying ptns who may benefit from im/m therapy, more validated evidence in other ptns cohorts is currently warranted.
§ Intensity of Macrophage Infiltration in Glomeruli Predicts Response to Immunosuppressive Therapy in Patients with IgA Nephropathy. Xie D, Zhao H, Xu X, Zhou Z, Su C, Jia N, Liu Y, Hou FF. J Am Soc Nephrol. 2021;